Abstract

Scintigraphy of the skeletal system is performed mainly with the use of 99mTc-MDP. There are other radiopharmaceuticals showing affinity to bone lesions: 99mTc-MIBG, 201Tl, 131I (in the case of papillary or follicular thyroid cancers), and 99mTc (V) DMSA (in the case of medullary cancer). Currently, positron emitted radioisotopes are also used in clinical practice. It seems that 18F-NaF/PET is a highly sensitive and specific modality for detection of metastases and other bone lesions. Certain data concerning the role of 18F-FDG, 18F-choline, or 68Ga-DOTATATE can be found. The aim of this article is to review the role of 18F-NaF and 18F-FDG in diagnosis of bone metastases.

Links

Aggregator Full Text

Authors

Tarnawska-Pierścińska M, Hołody Ł, Braziewicz J, Królicki L

Institution

Department of Nuclear Medicine, Holycross Cancer Centre, Kielce, Poland. m_tarnawska@interia.pl

Source

Nuclear medicine review. Central & Eastern Europe 14:2 2011 pg 105-8

MeSH

Bone Neoplasms
Fluorine Radioisotopes
Fluorodeoxyglucose F18
Humans
Magnetic Resonance Imaging
Positron-Emission Tomography
Radiopharmaceuticals
Sodium Fluoride
Technetium Tc 99m Medronate
Tomography, X-Ray Computed

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

22219151